# BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

> **NCT02963688** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 298 (actual)

## Conditions studied

- To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer

## Interventions

- **GENETIC:** Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform

## Key facts

- **NCT ID:** NCT02963688
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2016-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963688, "BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02963688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*